Clinical Trial Update: A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating long-term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED